Skip to main content
PharmaCielo Ltd. logo

PharmaCielo Ltd. — Investor Relations & Filings

Ticker · PCLO ISIN · CA71716K1012 LEI · 5493002XOFWMT83TYQ57 TSXV Manufacturing
Open in API
Filings indexed 389 across all filing types
Latest filing 2023-05-01 Regulatory Filings
Country CA Canada
Listing TSXV PCLO

About PharmaCielo Ltd.

https://www.pharmacielo.com/

PharmaCielo Ltd. is a global supplier specializing in the cultivation, processing, and distribution of medicinal-grade cannabis extracts and dried flower. The company focuses on ethical and sustainable production, aiming to be a leading partner in the global medicinal cannabis market. Utilizing ideal equatorial conditions, PharmaCielo operates large-scale, high-efficiency production facilities, including 12 hectares of open-air greenhouses, enabling four full crops annually for reliable supply. Its product portfolio includes standardized extracts, such as high-purity CBD Isolate, and both psychoactive and non-psychoactive derivatives. Production adheres to pharmaceutical-quality standards, supported by proprietary genetics maintained in a tissue culture lab and advanced processing facilities ensuring consistency and safety.

Recent filings

Filing Released Lang Actions
52-109FV1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings
2023-05-01 English
Annual MD&A - English.pdf
Regulatory Filings
2023-05-01 English
ON form 13-502F1 (class 1 and 3B reporting issuers - participation fee).pdf
Regulatory Filings
2023-05-01 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a strategic partnership between PharmaCielo and CANNPRISMA to supply EU-GMP certified dried flower to the European medicinal cannabis market. It also includes information about share issuance for debt settlement and stock option grants. The content is primarily an announcement of business developments and financing activities rather than a detailed financial report or regulatory filing. There are no financial statements, audit information, or detailed management discussion of financial results. The document is longer than 5,000 characters but does not contain substantive financial data or detailed report content. It is not a report publication announcement since it does not mention the release or availability of a report. The focus on share issuance and stock options aligns with capital/financing updates. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2023-04-19 English
News release - English.pdf
Capital/Financing Update Classification · 90% confidence The document is a press release announcing that PharmaCielo has received a purchase order for CBD Isolate as an API from a Brazilian pharmaceutical company, representing a commercial development and customer acquisition update. It also announces the engagement of a market maker (ITG) for trading services. The content is focused on business updates, sales orders, and market-making arrangements rather than financial results, regulatory filings, or detailed financial reports. There are no financial statements, earnings data, or management discussion of financial results. The document is a corporate announcement about sales and market activities, not a formal financial report or regulatory filing. Therefore, the best fitting category is Capital/Financing Update (CAP), as it relates to commercial sales orders and market-making engagement, which are capital market-related updates.
2023-02-08 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a corporate update press release from PharmaCielo Ltd. It discusses progress on efficiency initiatives, intentions to amend warrant terms, and issuance of shares for debt. There are no detailed financial statements or comprehensive financial data presented. The document focuses on operational updates, management actions, and capital structure changes (warrant amendments and share issuance). It is not an earnings release since it lacks financial results highlights, nor is it a full annual or interim report. The primary content relates to financing activities (warrant amendments and share issuance for debt). Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (9046 characters) and content confirm it is a substantive announcement rather than a brief notice or regulatory filing.
2023-02-02 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.